F5
EstablishedFactor V Leiden is the most common inherited thrombophilia, tested selectively rather than universally.
Factor V Leiden is the most common inherited clotting risk gene variant. It raises the risk of blood clots, but most carriers never actually develop one, which is why doctors don't recommend testing everyone — only people whose results would actually change their care.
F5 encodes coagulation factor V; a specific mutation, Factor V Leiden, makes the protein resistant to inactivation by activated protein C, making it the most common inherited thrombophilia and a leading genetic risk factor for venous thromboembolism.
Factor V Leiden carriers have elevated VTE risk (roughly 3-8x for heterozygotes, much higher for homozygotes), and the mutation has also been studied in obstetric complications (recurrent pregnancy loss, preeclampsia) and in acute coronary syndrome in younger patients, though evidence for the latter associations remains inconsistent.
Diagnosed via genetic testing for the specific F5 gene variant (rs6025); current guidelines from evidence-based working groups discourage routine testing for patients with VTE and their family members, recommending it only when results would influence management decisions.
The 2021 American College of Chest Physicians guidelines no longer include specific recommendations for pregnant women with known Factor V Leiden, a change from the 2012 edition, reflecting evolving evidence about how much this status should influence pregnancy management.
Most carriers never develop a clot; testing recommendations have narrowed over time, including in pregnancy management guidance.
- Grody, W. W., et al. Technical standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing).
- PMC. (2020). Direct-to-consumer genetic testing for factor V Leiden and prothrombin 20210G>A.